BioMarin Q1 revenue $649M (+9% YoY); raises non-GAAP EPS and margin guidance

BIOMARIN PHARMACEUTICAL INC

2024-Q1 EPS reported $0.46 revenue$648,833,000

GAAP diluted EPS $0.46 (+70% YoY); Non-GAAP diluted EPS $0.71 (+18% YoY).
VOXZOGO revenue $153M (+74% YoY); over 3,100 children treated (+102% YoY).
Full-year 2024 total revenue reaffirmed; non-GAAP margin and EPS guidance raised on $35-40M net OpEx savings.
R&D portfolio prioritized: accelerated BMN 333, BMN 349, BMN 351; discontinued BMN 331, 255, 355, 365.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOMARIN PHARMACEUTICAL INC reported first quarter ended March 31, 2024 results: revenue $648.8 million, net income $88.7 million, EPS $0.46. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $648.8 million
Net income: $88.7 million
EPS: $0.46
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Record Financial Results for the First Quarter 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO ® Net

View on SEC.gov

493 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-24-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.